MAP2K7 and melanoma: We predicted the drug response of RAF inhibitor (dabrafenib) and MEK inhibitor (trametinib) in three pre-treatment and matched post-relapse BRAF-mutant RAF/MEK inhibitor-resistant melanoma patients.